Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Royal Numico/Rexall Sundown Eyes Private Label As Key Growth Area

This article was originally published in The Tan Sheet

Executive Summary

Combined Royal Numico/Rexall Sundown operations regard their potential for private label sales in the U.S. mass market to be "very high," the firms reported during a May 1 teleconference. Numico and Rexall have little presence in U.S. private label now but appear to be pondering it for the future despite the traditional low margins of the products.

Related Content

GNC Goes For $750 Mil. As Numico Exits Dietary Supplement Industry
Met-Rx Ad Campaign Interweaves Science, Product Performance Benefits
GNC Sales Increase 10% In 2000, Capture 14.9% Market Share
Numico Consolidation Of Rexall, GNC Operations To Save $36 Mil.
Numico Supplement Sales Up Over 1300% Due To GNC, Rexall Acquisitions
Rexall Sundown
GNC Reorganization Focuses On Retailing; Mfg. To Fall Under New Unit
Royal Numico/Rexall
Numico Rexall Showcase Intl. Purchase Heightens Direct Sales Presence
GNC To Gain Broad R&D Pipeline From New Owner Royal Numico





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts